By using this site, you are consenting to our use of cookies. To find out more visit our privacy policy.
Global Deterioration Scale for Assessment of Primary Degenerative Dementia (GDS)
Summary
What it measures:
The Global Deterioration Scale (GDS) is a screening tool that helps caregivers/health care professionals determine the status of a patient’s primary dementia, with regard to the progression of their disease, as well as to determine a patient’s future expectations based on their current cognitive status. A categorical table classifies patients in specific stages of dementia. There are 7 stages incorporated into the GDS. Stage 1 on the scale is “no cognitive decline,” while Stage 7 on the scale is “very severe cognitive decline.” Each stage reflects upon an individual patient’s cognitive decline, based on several clinical characteristics and psychometric concomitants. Instead of assigning patients a numerical score, a clinician compares an individual based on their cognition and function to the criteria on the GDS, and uses their best judgement to choose the most appropriate stage. (1)
To establish a quick and more concise screening tool to detect early onset of dementia as well as the severity of the condition, the Modified GDS was created by using 5 individual items from the 7 GDS stages. There are 31 items on the GDS questionnaire that are used to assess a patient’s cognitive status, and 5 of the items were found to be the best predictors of dementia, referred to as Stage 20, 30, 8, 25, and 31 in this study. These are not to be confused with the original GDS stages 1-7. The Modified GDS was found to be just as effective as the full GDS 31 questionnaire in screening for dementia. The Modified GDS is used as a quick screening tool to detect the early onset of dementia as well as the severity of the condition. Before this tool is approved for clinical use, further psychometric testing is necessary. (2)
Target Population:
This summary contains information on use of this test in patients with primary progressive dementia, including Alzheimer disease. Included is information for the original GDS and for the Modified GDS.
In our opinion, the GDS can be used in the physical therapy setting for evaluating the severity of patients who are already diagnosed with dementia. Using this assessment tool can help us understand what stage of dementia the patient is in and what signs/symptoms to expect when working with an individual. This can help us determine the best plan of care for the patient, and help us think of appropriate interventions with regard to the patient’s presenting symptoms to maximize the effectiveness of treatments used. This tool also may help us to educate the patient’s family or caregiver regarding the symptoms to expect, based on the patient GDS classification stage. This is important for the family to ensure the patient’s safety and for prevention of safety, especially as the disease progresses over time.
Members Only Content
Join APTA to get unlimited access to content including evidence-based research, guidance on payment changes, and other resources to help you thrive. Learn more about membership benefits.
Already a member? Log in
Date: August 22, 2017
Contact: practice@apta.org
Content Type: Test & Measure
Michele Stanley, PT, DPT, Board-Certified Geriatric Clinical Specialist
You Might Also Like...
CPG
Dementia: Assessment, Management and Support for People Living With Dementia and Their Carers [NG97]Dec 16, 2020
This guideline provides recommendations related to diagnosis and management of patients with dementia.
Clinical Summary
DementiaMay 29, 2017
PTs work with patients with dementia to address mobility and strength limitations, minimize fall risk factors, and enhance the patient’s quality of life.
CPG
Recommendations on Screening for Cognitive Impairment in Older AdultsJan 5, 2016
Recommendations on screening for cognitive impairment in adults with a focus on assessing asymptomatic adults.